Kornimate/medical-research-clean huggingface dataset:
dietary vitamin a requirement in chinese children and the new technology of dietary assessment

Conditions: Vitamin A Deficiency

Summary: vitamin a deficiency remains a major public health problem in developing country worldwide. young children are considered to be at greatest risk of deficiency. however, there is little information on the vitamin a requirement of chinese children. in the present study, about 400 children aged between 4 and 9 years old in a kindergarten and an elementary school of shiyan city were screened before admission by questionnaire and anthropometric measurement. the vitamin a status of children was assessed by serum vitamin a level, relative dosage reaction and stable-isotope dilution technique. at the same time, their dietary vitamin a intakes were estimated by weighted-food dietary survey. the dietary vitamin a requirement in young children was determined on the basis of dietary vitamin a intakes in children with adequate vitamin a level.


Eligibility criteria:
inclusion criteria: * well-nourished children with normal serum retinol(\>=1.40umol/l) exclusion criteria: * ongoing or previous illnesses, * having taken nutritional supplements within 3 months, * positive results in the fat absorption test or parasite test, * increased level of crp (\> 8 mg/l), or * lower serum level of retinol (\< 1.40 umol/l)

Keywords: vitamin a dietary requirement dietary records deuterated retinol dilution technique chinese children dietary intake of vitamin a vitamin a liver reserves
pharmacodynamic study to better understand the therapeutic response and immunomodulatory effects of avonex in multiple sclerosis (ms) patients and healthy volunteers

Conditions: Multiple Sclerosis

Summary: this study will look at differences in bioanalytical measures among different groups of ms patients and healthy volunteers, when administered interferon beta-1a.


Eligibility criteria:
inclusion criteria: healthy control subjects (group 1) * must be in general good health. * must not have received interferons in the past. all ms subjects * clinical or laboratory-supported diagnosis of relapsing remitting ms (mcdonald et al, criteria numbers 1-4). * either on avonex® or treatment-naïve. * have an edss score between 0.0 and 5.5, inclusive. exclusion criteria: * history of severe allergic or anaphylactic reaction or hypersensitivity to human albumin, to any interferon, to other components of the drug formulation. * history of intolerance to acetaminophen, ibuprofen, naproxen, and aspirin that would preclude the use of at least one of these during the study. * history of any clinically significant (as determined by the investigator) cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease. * history of malignancy. * the presence of any significant medical condition or psychiatric illness not due to ms that, in the investigator's opinion, would interfere with therapy * history of uncontrolled seizures within the 3 months prior to enrollment. * history of suicidal ideation or an episode of severe depression within the 3 months prior to enrollment. * serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., pneumonia, septicemia) within 8 weeks prior to enrollment. * positive for human immunodeficiency virus (hiv), hepatitis c antibody (hcv) or positive for hepatitis b surface antigen (hbsag) at screening. other inclusion and exclusion criteria apply as per protocol

Keywords: multiple sclerosis
effectiveness of a shared decision aid tool for cardiovascular risk prevention in hypercholesterolemic patients

Conditions: Hypercholesterolemia; Cardiovascular Risk

Summary: background: mediterraneans have traditionally a low cardiovascular risk, although emerging lifestyles might change the trend. the aim of this study is to assess if hypercholesterolemic patient involvement in the preventive decision with the help of a decision aid has an impact on cardiovascular (cv) risk reduction superior to usual care. method: the design is a cluster randomised clinical trial. participants are hypercholesterolemic patients (\>200 mg/dl or c-ldl\>130) from four primary care teams of barcelona. patients with previous cv events, age over 75 years or cognitive impairment are excluded. it is expected to create two cohorts of 139 patients each one. the randomisation is by doctor. intervention group will receive information about their cv risk and the risk and benefits of different preventive measures. they will have access to a decission aid that will help them in the choice of the preventive measures.the material (printed and software) is adapted to the catalan population using local cv risk tables and will meet the credible and discern criteria. study variables: sociodemographic variables, cv risk factors, subjective health (sf 12), decisional conflict, anxiety/depression, analytic controls, treatment, treatment adherence, compliance and resources use. basal evaluation and 3, 6, 12 month assessment. the study, financed by fis, will begin the 01-07-2007. results: the expected results are a higher reduction on the cv risk factors in the intervention group versus regular care. conclusions study will provide a tool to be used in spanish and catalan population.


Eligibility criteria:
inclusion criteria: * patients between 14 and 75 years old having the inclusion criteria and consulting for cardiovascular risk diseases (cvd) in these centers. * patients who allow to participate in this study exclusion criteria: * patients with mental disorders. * secundary cardiovascular risk patients

Keywords: cardiovascular diseases patient education primary health care consumer participation decision aids
assesment of the functional activity of platelets for the differential diagnosis of thrombocytopathies

Conditions: Immune Thrombocytopenia; Thrombocytopathy; Acute Leukemia; Hemorrhagic Disorders

Summary: the purpose of this study is to develop a highly sensitive method for assessing the functional activity of platelets for use in the differential diagnosis of thrombocytopenia and platelet defects.

the purpose of this study is to develop a highly sensitive method for assessing the functional activity of platelets using flow cytometry and turbidimetric and impedance aggregometry for use in the differential diagnosis of thrombocytopenia and platelet defects

Eligibility criteria:
inclusion criteria: * pediatric participants with hemorrhagic syndrome (hemorrhagic rash, bruising, bleeding, increased bleeding of the skin and mucous membranes, spontaneous hemorrhages in soft tissues and joints) * pediatric participants with acute leukemia * parameters of the plasma level of blood coagulation correspond to the age normal levels exclusion criteria: * anticoagulation drug therapy * antiaggregation drug therapy * biologically active additives
multimodal analysis and electroretinogram in vkh from acute onset - part i

Conditions: Uveomeningoencephalitic Syndrome; Inflammation; Choroid Disease; Visual Impairment

Summary: patients with acute onset vogt-koyanagi-harada disease (vkhd) were prospectively included in this study. they were systematically followed with clinical, posterior segment imaging exams and full-field electroretinogram during a minimum 24-month of follow-up. all patients were treated with 3-day methylprednisolone pulse therapy followed by 1mg/day oral prednisone with a slow tapper during a median of 13 months. non-steroidal immunosuppressive therapy (imt) was introduced in cases of refractory disease or in cases of prednisone intolerance. outcome measured by full-field electroretinogram was analyzed and patient was grouped as electroretinogram stable or electroretinogram worsening. clinical data was analyzed in these two electroretinogram-based groups.

consecutive patients with acute onset vkhd were included and followed for a minimum 24-month as part i of an ongoing prospective long-term study on vkhd. the main purpose was to understand the course of clinical and subclinical choroidal inflammation in patients receiving early and high-dose corticosteroid followed by high-dose oral prednisone and a very slow tapper. all patients were followed with clinical and posterior segment imaging (psi) exams, i.e. fundus picture, fluorescein angiography, indocyanine green angiography and enhanced depth imaging optical coherence tomography, at inclusion, 1st month, and thereof every three months. full-field electroretinogram was performed at inclusion, 1st month, and thereof every six months. flare was defined as appearance or increase/worsening of inflammatory signs after the initial six-month from disease onset during the predefined treatment protocol. inflammatory signs were cells in anterior chamber, macular edema; subclinical inflammatory signs were mainly those observed by psi exams. scotopic full-field electroretinogram results between 12 and 24 month were the main outcome. clinical data was analyzed in the full-field electroretinogram-based groups.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of vogt-koyanagi-harada disease * acute onset with no previous treatment exclusion criteria: * non-acute vkhd * media opacities
hypersensitivity reactions to propofol in children

Conditions: Hypersensitivity; Allergy, Egg; Soy Allergy

Summary: the investigators would only include the children who received propofol (propolipid, fresenius kabi, schelle, belgium) for sedation, the investigators would exclude the children that didn't receive propofol during the procedure. the investigators would analyze the incidence of hypersensitivity reaction to propofol in children allergic to egg, soy or both egg and soy and to compare those with the incidence of hypersensitivity reactions in children without allergy to egg and/or to soy. those data were retrieved following longitudinal follow-up after the intervention. allergy tests by skin and radioallergosorbent tests were performed in all children before the gastrointestinal endoscopy under anesthesia took place, but no results were known at the time of the sedation. a patient was defined as allergic to egg and/or soy if the patient had specific s-ige level more than the normal level set by our institution (0.35 ku/l). the investigators would also investigate the influence of other obtained parameters in the dataset (age, asa score, weight category, type of investigation, respiratory and neurological comorbidities, respiratory infections, gerd, other allergies) on those results with multivariate analysis. we considered that clinical features suggesting a hypersensitivity reaction present during anaesthesia were cutaneous, respiratory or cardiovascular manifestations. depending on the severity of the reaction, necessitating prompt hemodynamic resuscitation with the administration of epinephrine, antihistamines, inhaled beta-agonists or corticosteroids.


Eligibility criteria:
inclusion criteria: * diagnostic gastrointestinal endoscopy * monitored anesthesia * received propofol during the procedure * allergic to egg and/or soy if the patient had specific s-ige level more than the normal level set by our institution (0.35 ku/l) exclusion criteria: * procedure without administration of propofol
diagnostic accuracy of nice classification to predict deep submucosal invasion

Conditions: Colonic Polyps

Summary: the purpose of this study is to evaluate the diagnostic accuracy of nice classification to predict deep submucosal invasion of colonic polyps \> 1 cm, considering histology as the gold standard, in a group of endoscopists who previously performed a training program.

in the first phase of the study, a learning program of nice classification based on examples will be performed. forty images will be evaluated before and after the learning program. in the second phase of the study, all consecutive patients who underwent to a colonoscopy will be included if a lesion greater than 1 cm is found and the endoscopy is performed with a high definition colonoscope with narrow band imaging (nbi). patients, lesions and endoscopy equipment characteristics will be recorded. subsequently, histological diagnosis of the lesion will also be recorded. evaluated test (nice classification) was blinded to the pathologist who performed the gold standard test (histology). in case of adenocarcinomas, histological predictors of lymph node metastases, with predefined assessment criteria, will also be recorded. finally, histological preparations of adenocarcinomas will be sent to the reference center and two experienced pathologists will examine them again.

Eligibility criteria:
inclusion patients criteria: * patients\> 18 years * lesion type 0 of paris classification, greater than 1 cm, found in a colonoscopy performed by any medical indication with a high definition endoscope with narrow band imaging. * achievable histology by endoscopic or surgical resection. * writing informed consent given. exclusion patients criteria: * age \<18 years. * refusal to give informed consent. * contraindication for endoscopic or surgical resection. * urgent colonoscopy indication (eg severe rectorrhagia.). * patients with inflammatory bowel disease. * suspected metastatic neoplasia by previous imaging tests. exclusion lesions criteria: * polyp previously biopsied or resected. * poor preparation that does not allow a proper assessment of the lesion. * nbi not performed. * unavailable or indefinite histology (endoscopic or surgical resection).

Keywords: nbi nice classification deep submucosal invasion colonic polyps [c23.300.825.411.235] colonoscopy [e01.370.372.250.250.200]
pain and medication use following surgery

Conditions: Opioid Use

Summary: patients will be randomized to one of two interventions intended to facilitate safe disposal of opioids after cessation following surgery. for pragmatic reasons, participants will be randomized by day to either the information sheet or the disposal bag using a block randomization schedule. to ensuring adequate sample size, patients will be enrolled for a \~4-week period following the 2-week usual care run in period. in the event that the sample size estimate has not been reached after the 4-week intervention period, additional patients will be enrolled accordingly.

the lack of evidence-based guidelines for postoperative opioid prescribing has contributed to a surplus of opioid pills within our patients' homes and communities, increasing the potential for diversion and nonmedical use. a recent study suggests that for outpatient general surgery procedures, roughly 72% of prescribed opioids go unused. current opioid disposal options are limited to dea-authorized opioid collectors, including select law enforcement agencies, pharmacies, or organized pill drop events, and many patients remain unaware of these avenues. several studies have found that few patients have knowledge about opioid disposal options and even fewer dispose of their unconsumed opioids. unconsumed opioids pose a diversion risk. in the 2011 national survey on drug use and health, 70.8% of those who used a prescription medication non-medically obtained the medication from a friend or relative, with or without their knowledge. additionally, nonmedical prescription opioid use is a common pathway to heroin use. importantly, over 80% of young intravenous drug users report initiation of prescription opioid misuse prior to heroin. considering that 40% of the prescriptions written by surgeons are for opioids and patients frequently have excess opioids and limited options for and/or knowledge of opioid disposal, the present study will provide patients with information and novel options for opioid disposal as part of the surgical care pathway.

Eligibility criteria:
inclusion criteria: * scheduled for surgery at michigan medicine's east ann arbor ambulatory surgery \& medical procedures center exclusion criteria: * unable to speak english * inability to understand or complete the surveys * other conditions that preclude meaningful participation in the study

Keywords: drug disposal
randomized controlled trial to evaluate surgical approaches to gastric cancer invading the esophagus (jcog9502)

Conditions: Gastric Neoplasm

Summary: to compare left thoraco-abdominal approach with abdominal and transhiatal approach to cardia or subcardia cancer

for gastric cancers with esophageal invasion (siewert type ii and iii), thoraco-abdominal approach has shown better survival results than abdominal approach in retrospective analyses. however, patients having mediastinal nodal metastasis have poor prognosis and the benefit of thoraco-abdominal approach is still controversial. we evaluated the two approaches in a prospective randomized trial.

Eligibility criteria:
inclusion criteria: 1. histologically proven adenocarcinoma 2. 75 years old or younger 3. forced expiratory volume in one second ≥ 50 % 4. arterial oxygen pressure in room air ≥ 70 mmhg 5. clinically t2/t3/t4 with ≤3 cm esophageal invasion 6. written consent exclusion criteria: 1. carcinoma in the remnant stomach 2. borrmann type 4 (linitis plastica) 3. synchronous or metachronous malignancy in other organs except for cervical carcinoma in situ and colorectal focal cancer in adenoma 4. history of left thoracotomy, or left pleural adhesion 5. past history of myocardial infarction or positive results of exercise ecg 6. liver cirrhosis, or chronic liver disease with indocyanine green test ≥15%

Keywords: stomach neoplasms lymph node resection cardia thoracotomy
efficacy of tyrosine in restless legs syndrome

Conditions: Restless Legs Syndrome (RLS)

Summary: tyrosine is a non essential amino acid that is the precursor of the neurotransmitter, dopamine. tyrosine is converted into levodihydrophenylalanine (l-dopa) and l-dopa is subsequently and avidly converted into dopamine. it is well known that dopamine deficiency leads to the manifestations of restless legs syndrome (rls). studies have shown dopamine agonists and l-dopa to be effective in controlling symptoms. no studies to date have been done to determine the role of tyrosine in rls. this open-label pilot study aims to determine the efficacy and tolerability of tyrosine in rls, as current agents have limitations in treating rls in addition to adding another possible agent to the investigators arsenal of treating rls that maybe more cost efficient. in this pilot study, the dose of tyrosine will be escalated from 750 mg once daily by mouth (po) up to 3000 mg once daily po, as tolerated, in increments of 750 mg every week in patients who meet the inclusion criteria for rls. patients' symptoms will be monitored on a weekly basis for six weeks.


Eligibility criteria:
inclusion criteria: 1. men and women aged 18 to 80 years and 2. newly diagnosed (medication-naïve) as having restless legs syndrome (using the international restless legs syndrome study group (irlssg20) diagnostic criteria with a score of greater than or equal to 15, see appendix a) and 3. that interfered with sleep onset and/or maintenance for greater than four nights/week for a minimum of six months 4. currently not receiving treatment for rls exclusion criteria: 1. patients suffering from secondary rls (other movement and/or primary sleep disorders, chronic renal insufficiency - calculated from the creatinine clearance, and/or iron deficiency - baseline serum ferritin level less than 10 ng/ml) 2. patients currently on pharmacotherapy for rls (not medication-naïve) or previous use of pharmacotherapy for rls in the past 3. patients that are pregnant and/or breastfeeding 4. patients that are on levothyroxine or monoamine oxidase inhibitors

Keywords: rls
the application of photosensitive hydrogel in intranasal endoscopic dacryocystorhinostomy

Conditions: Chronic Dacryocystitis

Summary: to study the effect of photosensitive hydrogel used for suture free anastomosis of lacrimal cyst and nasal mucoperiosteal flap in endoscopic nasal dacryocystostomy, and evaluate its adhesion to lacrimal cyst and nasal mucoperiosteal flap, promoting wound healing, forming a good anastomosis, preventing postoperative anastomosis and shortening operation time. twenty patients with chronic dacryocystitis were randomly divided into photosensitive hydrogel group and suture group.symptoms and nasal endoscopy were followed up 2, 6, and 12 weeks after surgery for both groups. and also adverse events were recorded at each follow-up.

after endoscopic dacryocystonasal anastomosis, granulation and/or cicatricial adhesion are the main reasons for surgical failure. how to achieve the ideal fit between the lacrimal sac flap and the nasal mucoperiosteal flap and avoid the proliferation of granulation and cicatricial adhesion is very important for the success of the operation. in this study, "photocoupling reaction" technology was used to achieve seamless integration and strong adhesion of photosensitive hydrogel materials to the wound, and the photohydrogel was applied to suture free adhesion and wound repair of the lacrimal cyst mucosal flap and nasal mucosal flap in endoscopic nasal dacryocystostomy (en-dcr), and its feasibility, safety and effectiveness were evaluated.

Eligibility criteria:
inclusion criteria: 1. voluntarily participate in this clinical study and sign the informed consent; 2. gender is not limited, age 18-75 years old; 3. the patient had symptoms and signs of chronic dacryocystitis, and the results of lacrimal passage irrigation suggested that the lower rush and return or upper rush and lower return, accompanied by mucous or purulent discharge reflux; 4. lacrimal duct angiography suggests nasolacrimal duct obstruction without lacrimal canaliculi and/or duct obstruction. exclusion criteria: 1. age \ 75 years old; 2. previous history of dacryocystonasal anastomosis; 3. abnormal coagulation function; 4. tumors of lacrimal passage, especially in patients with papilloma or malignant tumors; 5. in the acute dacryocystitis attack stage; 6. obvious scar constitution; 7. complicated with serious nasal diseases, such as severe allergic rhinitis, chronic rhinosinusitis and nasal polyps, acute suppurative rhinosinusitis, severe atrophic rhinitis, and severe deviation of nasal septum; 8. have serious heart, liver, kidney, lung and other basic diseases, can not tolerate general anesthesia; 9. distance from the hospital, postoperative review is not convenient; 10. participated in other clinical trials within the last 3 months; 11. any medical history that the investigator determines may interfere with the test results or increase the patient's risk.